Human medicines European public assessment report (EPAR): Atectura Breezhaler, indacaterol,mometasone, Date of authorisation: 30/05/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Enerzair Breezhaler, indacaterol,glycopyrronium bromide,mometasone, Date of authorisation: 03/07/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Gobivaz, golimumab, Date of authorisation: 17/11/2025, Status: Authorised

ADHD medicines

Classification of a product as intended for a limited market and eligibility for authorisation under Article 23 of Regulation (EU) 2019/6 (Applications for limited markets)

EMEA-003153-PIP01-21

First-in-class treatment to delay onset of type 1 diabetes

Human medicines European public assessment report (EPAR): Dafiro, amlodipine,valsartan, Date of authorisation: 15/01/2007, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Copalia, amlodipine,valsartan, Date of authorisation: 15/01/2007, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Exforge, amlodipine,valsartan, Date of authorisation: 16/01/2007, Revision: 35, Status: Authorised